Springworks therapeutics announces long-term efficacy and safety data from phase 3 defi trial of ogsiveo® (nirogacestat) in adults with desmoid tumors to be presented at the connective tissue oncology society (ctos) 2024 annual meeting

– long-term follow-up data highlight further reductions in tumor size, increase in orr with additional crs, sustained improvement in desmoid tumor symptoms, and consistent safety profile, now with a median duration of therapy of approximately 3 years –
CTOS Ratings Summary
CTOS Quant Ranking